Clinicopathologic features of retinoblastoma and expression of VEGF and Ki-67 after comprehensive treatment

Chinese Journal of Ophthalmology

Volumn 47, Issue 2, 2011, Pages 134-141

  Xue, Kang ^a   Qian, Jiang ^a   Bi, Ying Wen ^a   Yao, Yi Qun ^a   Yuan, Yi Fei ^a   Da, Cui Di ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Combined modality therapy; Ki 67 antigen; Retinoblastoma; Vascular endothelial growth factor A

Indexed keywords

KI 67 ANTIGEN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER STAGING; FEMALE; HUMAN; INFANT; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRESCHOOL CHILD; RETINA TUMOR; RETINOBLASTOMA; RETROSPECTIVE STUDY;

CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFANT; KI-67 ANTIGEN; MALE; NEOPLASM STAGING; RETINAL NEOPLASMS; RETINOBLASTOMA; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 82255169371     PISSN: 04124081     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.04124081.2011.02.008     Document Type: Article

References (16)

1. 2007, 43: 481-483.
2. Kingston JE, Hungerford JL, Madreperla SA, et al. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol, 1996, 114: 1339-1343.
3. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma withour radiotherapy. Arch Ophthalmol, 1996, 114: 1321-1328.
4. Murphree AL, Villablanca JG, Deegan WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol, 1996, 114: 1348-1356.
5. Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology, 2006, 113: 2276-2280.
6. Demirci H, Eagle RC, Shields CL, et al. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Arch Ophthalmol, 2003, 121: 1125-1131.
7. Buys RJ, Abramson DH, Ellsworth RM, et al. Radiation regression patterns after cobalt plaque insertion for retinoblastoma. Arch Ophthalmol, 1983, 96: 315-320.
8. Singh AD, Garway-Heath D, Love S, et al. Relationship of regression pattern to recurrence in retinoblastoma. Br J Ophthalmol, 1993, 77: 12-16.
9. Shields CL, Palamar M, Sharma P, et al. Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. Arch Ophthalmol, 2009, 127: 282-290.
10. Ts'o MO, Zimmerman LE, Ellsworth RM. A cause of radioresistance in retinoblastoma: photoreceptor differentiation. Trans Am Acad Ophathalmol Otolaryngol, 1970, 69: 339-349.
11. Bechrakis NE, Bornfeld N, Schtiler A, et al. Clinicopathologic features of retinoblastoma after primary chemoreduction. Arch Ophthalmol, 116: 887-893.
12. Taheri ZM, Mehrafza M, Moharnmadi F, et al. The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. Arch Pathol Lab Med, 2008, 132: 694-697.
13. Ng IO, Na J, Lai EC, et al. Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1.A comparison with proliferating cell nuclear antigen. Am J clin Pathol, 1995, 104: 313-318.
14. 2005, 41: 155-158.
15. Tannock IF. Tumor physiology and drug resistance. Cancer Metastasis Rev, 2001, 20: 123-132.
16. Xu L, Cochran DM, Tong RT, et al. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotoopic mouse models. Cancer Res, 2006, 66: 3971-3977.